Canine immune-mediated polyarthritis: part 2: diagnosis and treatment.

Abstract

Canine immune-mediated polyarthritis (IMPA) is a diagnosis of exclusion based predominantly on clinical signs, characteristic joint fluid analysis, and elimination of potential joint infection. Ultimately, an appropriate and sustained response to immunosuppressive therapy may become the final diagnostic criterion used. Identifying associated disease processes, including breed-specific syndromes, remote infection, inflammation, drug exposure, vaccine exposure, or neoplasia, as well as initial response to therapy, is often an important contributor to prognosis. This review article is the second of a two part series and focuses on the diagnosis and treatment of immune-mediated polyarthritis. The first article in this series, published in the January/February 2012 issue, concentrated on the pathophysiology of IMPA.

• Authors: Kirstin C Johnson, Andrew Mackin
• Journal: Journal of the American Animal Hospital Association (J Am Anim Hosp Assoc) 2012 Mar-Apr Vol. 48 Issue 2 Pg. 71-82 ISSN: 1547-3317 [Electronic] United States
• PMID: 22267168 (Publication Type: Journal Article, Review)

Chemical References

• Immunosuppressive Agents

Topics

• Animals
• Arthritis (diagnosis, drug therapy, veterinary)
• Breeding
• Dog Diseases (diagnosis, drug therapy)
• Dogs
• Female
• Immunosuppressive Agents (therapeutic use)
• Joint Diseases (diagnosis, drug therapy, veterinary)
• Male
• Prognosis
• Treatment Outcome